U. Pittsburgh: Tumor Protein Patterns Predict Melanoma Immunotherapy Response

Protein patterns inside skin melanoma tumors can accurately predict patient responses to immunotherapy, revealing distinct biological subtypes that influence survival rates and treatment resistance.

Two new University of Pittsburgh studies, published on November 17 in the journals Cancer Discovery and Clinical Cancer Research by the American Association for Cancer Research, have mapped the molecular landscape of melanoma to create a classifier model for treatment outcomes.

Immune checkpoint inhibitors have transformed care for advanced melanoma over the last fifteen years, yet a large percentage of patients still fail to respond or eventually develop resistance. To pinpoint why some tumors evade treatment, researchers examined the proteome, which represents the entire set of proteins expressed in a tissue.

“In 2003, we decoded the human genome.”

Decoding the Melanoma Proteome and Subtypes

The study published in Cancer Discovery characterized pre-treatment melanomas from 183 patients by simultaneously analyzing 13 molecular levels, including the genome, proteome, and metabolome, in an approach known as multi-omics (A comprehensive proteogenomic, immunopeptidomic, and metabolomic atlas decodes immunogenicity in cutaneous melanoma). This comprehensive atlas identified chemical alterations to proteins associated with survival alongside hundreds of potential targets for future investigations.

Wang melanoma immunotherapy studies
Photo: Newswise

The companion study in Clinical Cancer Research utilized data from 208 tumor samples obtained prior to immunotherapy through an international collaboration involving NCI-funded Melanoma SPORE programs. Researchers identified three distinct subtypes characterized by unique protein patterns.

One subtype exhibited increased immune activity, another showed elevated features of cell proliferation, and a third displayed characteristics associated with tumor growth and metastasis. Each protein pattern group correlated differently with treatment response, with the immune-rich group demonstrating the highest responsiveness.

Classifying Patient Samples Prior to Treatment

Researchers trained a classifier model to sort tumors into one of the three identified subtypes based on protein patterns.

Amanda Paulovich, MD, PhD, of Fred Hutch Cancer Center noted the identification of a panel of 127 proteins capable of distinguishing among the three melanoma subtypes associated with different immunotherapy responses.

In Plain English: The Clinical Takeaway

  • Targeting the Proteome: While genes provide the blueprint, proteins do the actual cellular work. Analyzing proteins helps doctors see how a tumor behaves in real time.
  • Predictive Biomarkers: A newly validated panel of 127 proteins can sort melanoma tumors into three distinct subtypes, revealing which patients are most likely to benefit from immunotherapy.
  • Avoiding Ineffective Therapies: Identifying non-responders before treatment begins spares patients from severe side effects and allows clinicians to pursue alternative options faster.
Melanoma Protein Subtype Primary Characteristics Immunotherapy Association
Immune-Rich Group High baseline immune activity and tumor infiltration Most responsive to treatment
Proliferation Group Elevated features of cell division and growth Intermediate response / monitoring required
Metastatic Group Characteristics associated with tumor spread Associated with disease progression and resistance

Contraindications & When to Consult a Doctor

Patients considering immune checkpoint inhibitors should discuss comprehensive biomarker testing and potential immune-related adverse events with their medical oncologist. Individuals with pre-existing autoimmune disorders or those undergoing immunosuppressive therapy require careful clinical evaluation before starting checkpoint blockade, as these therapies can provoke severe autoimmune toxicities.

Patients experiencing persistent fatigue, unexplained fever, severe gastrointestinal changes, or new skin rashes during immunotherapy must contact their oncology care team immediately for prompt clinical triage.

Translating Biomarkers Into Clinical Practice

Further validation is required before these findings become standard clinical tools, but the research establishes a framework for personalized melanoma care. Translating these findings into a practical assay will allow local pathology laboratories to help determine individual treatment responsiveness before therapy begins.

We currently lack reliable biological markers to predict which patients will benefit from combination immunotherapy.

References

  • Gong, J., Petralia, F., Ruiz Cuevas, M. V., et al. (2026). A comprehensive proteogenomic, immunopeptidomic, and metabolomic atlas decodes immunogenicity in cutaneous melanoma. Cancer Discovery. DOI: 10.1158/2159-8290.cd-26-0302
  • American Association for Cancer Research. (2026). Clinical Cancer Research.
  • National Cancer Institute Clinical Proteomic Tumor Analysis Consortium (CPTAC). Research findings on cutaneous melanoma proteomics and immunotherapies.
Photo of author

Health Desk

Health Desk at Archyde.

Liverpool Target Brighton’s Bart Verbruggen as Alisson Successor